1 week Ago By Defense World Staff
Corebridge Financial Inc. reduced its position in shares of Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 7.
0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,050 shares of the company’s stock after selling 2,721 shares during the period. Corebridge Financial Inc.
’s holdings in Kura Oncology were worth $314,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Barclays PLC raised its stake in Kura Oncology by 104.
5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth about $436,000.
Moody Aldrich Partners LLC lifted its stake in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after purchasing an additional 42,712 shares during the last quarter.
Harbor Capital Advisors Inc. lifted its stake in Kura Oncology by 4.4% during the fourth quarter.
Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after purchasing an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Kura Oncology in the fourth quarter valued at approximately $623,000.
Kura Oncology Price PerformanceKura Oncology stock opened at $5.63 on Friday. The business has a 50 day simple moving average of $7.
42 and a 200-day simple moving average of $10.96. Kura Oncology, Inc.
has a 12 month low of $5.41 and a 12 month high of $23.48.
The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.
47. The stock has a market capitalization of $454.65 million, a PE ratio of -2.
39 and a beta of 0.83. Kura Oncology (NASDAQ:KURA – Get Free Report) last released its earnings results on Wednesday, February 26th.
The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.
43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.
96 million. Equities analysts predict that Kura Oncology, Inc. will post -2.
44 earnings per share for the current year. Insider Buying and Selling at Kura OncologyIn other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.
87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.
11. This trade represents a 5.32 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.
87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.
91. The trade was a 5.31 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock valued at $92,307. 5.
50% of the stock is owned by corporate insiders. Wall Street Analyst Weigh InSeveral brokerages have recently weighed in on KURA. Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, March 4th.
UBS Group reduced their price target on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th.
JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. StockNews.
com raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th.
Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.
50.View Our Latest Analysis on KURAAbout Kura Oncology (Free Report)Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.Featured StoriesFive stocks we like better than Kura OncologyThe Significance of a Trillion-Dollar Market Cap Goes Beyond a NumberJoby Aviation: Operational Momentum vs. Market SentimentWhat Does a Gap Up Mean in Stocks? How to Play the GapBroadcom’s Big Outperformance Shows Strength Amid Tariff DeclineExpert Stock Trading Psychology TipsCarvana: Can Turnaround Strength Outdrive Market Headwinds?Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Free Report)..
